# Sionna Therapeutics Inc. (SION)

Source: https://www.quantisnow.com/company/SION
Generated: 2026-11-08T06:23:12.153Z

- Ticker: SION
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2025
- SEC CIK: 0002036042

## Latest SION news and filings

- 2026-11-02 13:00 UTC [Conference Announcement] [Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences](https://www.quantisnow.com/insight/sionna-therapeutics-to-participate-in-upcoming-november-2026-investor-conferences-6766182)
- 2026-10-08 20:30 UTC [Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference](https://www.quantisnow.com/insight/sionna-therapeutics-to-present-data-at-the-2026-north-american-6741883)
- 2026-09-21 22:56 UTC [SEC Form 4] [Director Ra Capital Management, L.P. sold $21,835,018 worth of shares (3,448,811 units at $6.33) (SEC Form 4)](https://www.quantisnow.com/insight/director-ra-capital-management-lp-sold-21835018-worth-of-shares-6722147)
- 2026-09-21 22:57 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-sionna-therapeutics-inc-6722145)
- 2026-09-18 20:59 UTC [SEC Form 4] [CFO and CBO Ridloff Elena was granted 94,537 shares, increasing direct ownership by 245% to 133,069 units (SEC Form 4)](https://www.quantisnow.com/insight/cfo-and-cbo-ridloff-elena-was-granted-94537-shares-increasing-6720809)
- 2026-09-18 20:58 UTC [SEC Form 4] [CMO and Head of R&D Mckee Charlotte was granted 100,000 shares, increasing direct ownership by 352% to 128,415 units (SEC Form 4)](https://www.quantisnow.com/insight/cmo-and-head-of-rd-mckee-charlotte-was-granted-100000-6720778)
- 2026-09-18 20:56 UTC [SEC Form 4] [CLO and Head of Program Mgmt. Fitzpatrick Jennifer was granted 56,265 shares (SEC Form 4)](https://www.quantisnow.com/insight/clo-and-head-of-program-mgmt-fitzpatrick-jennifer-was-granted-6720771)
- 2026-09-18 20:52 UTC [SEC Form 4] [President & CEO Cloonan Michael was granted 218,050 shares, increasing direct ownership by 40% to 765,393 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-cloonan-michael-was-granted-218050-shares-increasing-direct-6720760)
- 2026-09-17 21:10 UTC [SEC Form 144] [SEC Form 144 filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-sionna-therapeutics-inc-6719579)
- 2026-09-14 20:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sionna-therapeutics-inc-6714468)
- 2026-09-14 20:01 UTC [Earnings Date] [Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial](https://www.quantisnow.com/insight/sionna-therapeutics-announces-plans-to-advance-sion-451-sion-2222-dual-combination-6714331)
- 2026-08-10 19:41 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by BTIG Research](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-btig-research-6673407)
- 2026-08-10 17:19 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by Guggenheim](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-guggenheim-6673291)
- 2026-08-10 15:48 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by Citizens](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-citizens-6673245)
- 2026-08-10 15:47 UTC [Analyst Upgrade] [Sionna Therapeutics upgraded by RBC Capital Mkts with a new price target](https://www.quantisnow.com/insight/sionna-therapeutics-upgraded-by-rbc-capital-mkts-with-a-new-6673242)
- 2026-08-10 15:45 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by Raymond James](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-raymond-james-6673239)
- 2026-08-10 15:05 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by Wedbush with a new price target](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-wedbush-with-a-new-price-target-6673211)
- 2026-08-10 13:26 UTC [Analyst Downgrade] [Sionna Therapeutics downgraded by Stifel with a new price target](https://www.quantisnow.com/insight/sionna-therapeutics-downgraded-by-stifel-with-a-new-price-target-6673120)
- 2026-08-10 11:15 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sionna-therapeutics-inc-6672655)
- 2026-08-10 11:00 UTC [Earnings Date] [Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update](https://www.quantisnow.com/insight/sionna-therapeutics-reports-topline-data-from-two-development-programs-in-6672566)
- 2026-08-06 11:19 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-sionna-therapeutics-inc-6667239)
- 2026-08-06 11:12 UTC [SEC Form 8-K] [Sionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition](https://www.quantisnow.com/insight/sionna-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6667221)
- 2026-08-06 11:00 UTC [Sionna Therapeutics Reports Second Quarter 2026 Financial Results](https://www.quantisnow.com/insight/sionna-therapeutics-reports-second-quarter-2026-financial-results-6667073)
- 2026-07-09 20:47 UTC [SEC Form 4] [Director Thompson Peter A. sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-thompson-peter-a-sold-3854281-worth-of-shares-85918-6633272)
- 2026-07-09 20:44 UTC [SEC Form 4] [Director Orbimed Advisors Llc sold $3,854,281 worth of shares (85,918 units at $44.86) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-sold-3854281-worth-of-shares-85918-6633256)
- 2026-07-07 20:38 UTC [SEC Form 4] [Chief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $446,862 worth of shares (10,250 units at $43.60) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-fitzpatrick-jennifer-exercised-10250-shares-at-a-6630278)
- 2026-07-02 20:45 UTC [SEC Form 4] [Director Thompson Peter A. sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-thompson-peter-a-sold-5270902-worth-of-shares-115844-6626067)
- 2026-07-02 20:42 UTC [SEC Form 4] [Director Orbimed Advisors Llc sold $5,270,902 worth of shares (115,844 units at $45.50) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-orbimed-advisors-llc-sold-5270902-worth-of-shares-115844-6626038)
- 2026-06-18 21:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Stelzer Laurie](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stelzer-laurie-6609497)
- 2026-06-18 21:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Viney Joanne L.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-viney-joanne-l-6609486)
- 2026-06-18 21:45 UTC [SEC Form 4] [SEC Form 4 filed by Director Thompson Peter A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-thompson-peter-a-6609481)
- 2026-06-18 21:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Ra Capital Management, L.P.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ra-capital-management-lp-6609478)
- 2026-06-18 21:39 UTC [SEC Form 4] [SEC Form 4 filed by Director Ruddy Marcella K.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ruddy-marcella-k-6609475)
- 2026-06-18 21:37 UTC [SEC Form 4] [SEC Form 4 filed by Director Resnick Joshua](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-resnick-joshua-6609471)
- 2026-06-18 21:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Fleming Harold Edward](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fleming-harold-edward-6609465)
- 2026-06-18 21:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Clancy Paul J](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-clancy-paul-j-6609461)
- 2026-06-18 21:29 UTC [SEC Form 4] [SEC Form 4 filed by Director Booth Bruce](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-booth-bruce-6609447)
- 2026-06-18 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-sionna-therapeutics-inc-6608560)
- 2026-06-01 16:39 UTC [SEC Form 144] [Amendment: SEC Form 144/A filed by Sionna Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-144a-filed-by-sionna-therapeutics-inc-6581242)
- 2026-05-30 01:02 UTC [SEC Form 4] [Director Thompson Peter A. sold $4,493 worth of shares (101 units at $44.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/director-thompson-peter-a-sold-4493-worth-of-shares-101-6580187)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SION
- Earnings history: https://www.quantisnow.com/earnings/SION
- Dividend history: https://www.quantisnow.com/dividends/SION
- Insider transactions: https://www.quantisnow.com/insiders/SION
- Options chain: https://www.quantisnow.com/options/SION
- SEC 8-K filings only: https://www.quantisnow.com/company/SION/8-k
- RSS and alerts for SION: https://www.quantisnow.com/docs/rss-feeds.md